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—Constantine P. Cavafy, Ithaka (1)C oronary ﬁbroatheromas can cause a widespectrum of adverse events, such as suddendeath, acute coronary syndromes, and pro-
cedural complications during percutaneous coronary
interventions (PCI) (2). Accurate ﬁbroatheroma detec-
tion could signiﬁcantly enhance our ability to treat
these lesions and prevent complications.
FIBROATHEROMA DETECTION DURING
CARDIAC CATHETERIZATION
Fibroatheromas can be detected noninvasively with
coronary computed tomography angiography. Three
imaging modalities are currently available for ﬁbro-
atheroma detection during cardiac catheterization:
intravascular ultrasonography (IVUS), optical coher-
ence tomography (OCT), and near-infrared spectros-
copy (NIRS) (3) (Figure 1).
Grayscale IVUS, which is the oldest and most
widely available intravascular imaging modality,
was not developed speciﬁcally for the detection of
ﬁbroatheroma. However, IVUS-attenuated plaqueals published in JACC: Cardiovascular Imaging reﬂect the views
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in HygeiaTel.(attenuation of the ultrasound beam in the absence of
calciﬁcation), especially when superﬁcial (closer to
the lumen than the media), is a speciﬁc (but not
sensitive) ﬁbroatheroma “signature” (4,5).
Analysis of the backscattered radiofrequency IVUS
signals (virtual histology IVUS and integrated back-
scatter IVUS) also allows plaque characterization, but
it is challenging to perform in real time during the
procedure because it requires accurate segmentation
of the IVUS images, which is a time-consuming and
labor-intensive process (3).
OCT identiﬁes ﬁbroatheromas as signal-poor re-
gions with ill-deﬁned borders (6), but OCT image
interpretation is subjective and highly dependent on
operator experience (3). Moreover, deep ﬁbroather-
omas may be harder to detect due to poor penetration
of the near-infrared light beam.
NIRS was developed to speciﬁcally detect lipid core
plaque in coronary arteries, on the basis of the spe-
ciﬁc chemical signature of the ﬁbroatheroma (7).
Near-infrared light is directed to the coronary artery
wall, and the reﬂected light is collected and analyzed
using algorithms developed based on histological
analyses (7). NIRS is currently available as a com-
bination catheter with IVUS (TVC, Infraredx, Bur-
lington, Massachusetts)—the only such catheter
currently in clinical use.SEE PAGE 184In this issue of iJACC, Kang et al. (8) advance our
understanding of ﬁbroatheroma detection with IVUS
and NIRS, compared with the gold standard, histology.
In an autopsy study of 103 coronary arteries from
56 autopsied hearts, they compared superﬁcial IVUS
attenuation (for IVUS) and a yellow or tan block che-
mogram (for NIRS) with the histopathology obtained
from 1,943 sections. Superﬁcial IVUS attenuation had
excellent speciﬁcity, yet low sensitivity for ﬁbroa-
theroma detection, which was signiﬁcantly improved
by NIRS. The addition of NIRS signiﬁcantly increased
FIGURE 1 Detection and Management of Coronary Fibroatheromas
Outline of the various invasive imaging modalities for ﬁbroatheroma detection and possible treatment strategies. CABG ¼ coronary
artery bypass graft surgery; IVUS ¼ intravascular ultrasound; NIRS ¼ near-infrared spectroscopy; OCT ¼ optical coherence tomography;
PCI ¼ percutaneous coronary intervention; RF-IVUS ¼ radiofrequency intravascular ultrasound.
Brilakis and Banerjee J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 8 , N O . 2 , 2 0 1 5
Editorial Comment F E B R U A R Y 2 0 1 5 : 1 9 5 – 7
196the accuracy of ﬁbroatheroma detection at the mini-
mum lumen area from 75% to 89% among all of
the cross sections (p < 0.05) and from 48% to 88%
(p < 0.05) in cross sections with IVUS-detected
calcium $35.5. When either superﬁcial IVUS atten-
uation or lipid-rich plaque were present, detection
of ﬁbroatheroma signiﬁcantly improved compared
with IVUS alone in the overall lesion group, although
NIRS alone performed very well at the tightest stenosis
cross section.
What do these ﬁndings mean for everyday clinical
practice? First, they conﬁrm that superﬁcial IVUS
attenuation is a highly speciﬁc ﬁnding for ﬁbro-
atheroma, which is especially important for centers
that do not have the combined NIRS/IVUS system.
Second, they demonstrate that the combined NIRS/
IVUS system has good performance characteristics for
ﬁbroatheroma detection, by allowing evaluation of
both structure and composition.
FIBROATHEROMA DETECTED: NOW WHAT?
What to do after a ﬁbroatheroma is detected during
cardiac catheterization is a work in progress (Figure 1).To date, there are no randomized, controlled clinical
trials demonstrating that procedure modiﬁcation on
the basis of ﬁbroatheroma detection improves clinical
outcomes. Nevertheless, the following courses of ac-
tion can be considered.
First, ﬁbroatheroma detection could help identify
the culprit lesion (or lack thereof) for an acute
coronary syndrome, in cases in which angiographic
ﬁndings are inconclusive.
Second, ﬁbroatheroma detection within a lesion for
which PCI is planned suggests a high risk for peri-
procedural myocardial infarction (9,10) due to distal
embolization and/or aggressive in situ thrombus for-
mation (11). Potential clinical strategies to mitigate
this risk include vasodilator administration (nicardi-
pine is the authors’ preferred medication due to
longer half-life and modest hypotensive effect),
aggressive anticoagulation (with addition of a glyco-
protein IIb/IIIa inhibitor, which is usually given as
bolus only without post-PCI infusion), attempts for
plaque “vaporization” (e.g., by using laser), and
deployment of an embolic protection device (usually
a ﬁlter that can capture both embolized plaque and/or
thrombus) (12). Although these steps are logical, their
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197use remains empiric and pre-supposes signiﬁcant
local expertise in complex coronary interventions and
use of embolic protection devices. Moreover, use of
embolic protection devices in native coronary arteries
is off-label (they are only approved for use in saphe-
nous vein grafts).
Third, ﬁbroatheroma detection within a lesion
treated with PCI may allow for optimal stent selection
(13). Using a long-enough stent to completely cover
the ﬁbroatheroma may reduce the rate of acute stent
thrombosis (14), and possibly restenosis.
Fourth, ﬁbroatheroma detection within non-PCI
target lesions identiﬁes the artery and the patient as
potentially being at high risk for coronary events
that could potentially be lowered by intensive medi-
cal therapy. In patients with multiple obstructive
lesions and ﬁbroatheromas, revascularization with
coronary artery bypass graft surgery may allow pro-
tection of multiple myocardial areas “at risk,”
although this hypothesis remains to be proven. In
the PROSPECT (Providing Regional Observations to
Study Predictors of Events in the Coronary Tree)
study, the highest risk plaques (thin cap ﬁbroather-
omas with $70% plaque burden and #4 mm2 mini-
mum lumen area) had an 18.2% 3-year risk for causing
a major adverse cardiac event (15). Whether ﬁbroa-
theroma detection using NIRS/IVUS will provide
better discrimination for future events is currentlybeing examined in several studies, such as the (LRP)
Lipid-Rich Plaque study (NCT02033694) and the
PROSPECT II (A Multicentre Prospective Natural His-
tory Study Using Multimodality Imaging in Patients
With Acute Coronary Syndromes) trial (NCT02171065).
The study has important limitations. Whether
additional imaging information (e.g., measurement of
cap thickness using OCT) will enhance the predictive
capacity of NIRS/IVUS ﬁndings and the optimal choice
of lesion treatments (either local, e.g., bioabsorbable
scaffold implantation, or systemic, e.g., a high-dose
statin or in the future administration of a proprotein
convertase subtilisin/kexin type 9 inhibitor) will
require additional studies. Additional studies are also
needed to determine that the performance of NIRS/
IVUS in vivo matches the performance observed in
this autopsy study. Unraveling the secrets of ﬁbro-
atheromas and their optimal management promises
to be a long voyage, full of adventure and discovery,
yet with important critical implications for our
patients and our practices.
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